Lv4
520 积分 2024-05-01 加入
Targeting Solid Tumors with Bispecific T Cell Engager Immune Therapy
6个月前
已完结
Recognizing, defining, and managing CAR-T hematologic toxicities
7个月前
已关闭
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network
7个月前
已完结
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
7个月前
已完结
Bispecific antibodies for targeted delivery of anti-cancer therapeutic agents: A review
7个月前
已完结
Bispecific Antibodies and Autologous Chimeric Antigen Receptor T cell therapies for Treatment of Hematological Malignancies
8个月前
已完结
Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review
8个月前
已完结
Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review
8个月前
已完结
T-cell-engaging bispecific antibodies in cancer
8个月前
已完结
皖公网安备34019202002308
